Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
12:11pm, Wednesday, 10'th Sep 2025
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
This Small Biotech Stock Is Surging Today. Here's Why.
12:35pm, Tuesday, 09'th Sep 2025
Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
09:05am, Tuesday, 09'th Sep 2025
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company for $1.4 billion.
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
08:16am, Tuesday, 09'th Sep 2025
GLP-1 drugs are taking much oxygen out of the biotechnology trade. However, many investors have been eyeing other areas in the sector, particularly cancer research.
This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.
07:28am, Tuesday, 09'th Sep 2025
Novartis agrees to acquire Tourmaline Bio in an all-cash deal worth around $1.4 billion.
Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal
06:44am, Tuesday, 09'th Sep 2025
Nebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentially expanding to $19.4B. Novartis acquires Tourmaline Bio for $1.4B in cash, a 59% premium, highligh
Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range
05:39am, Tuesday, 09'th Sep 2025
Novartis on Tuesday said it was buying a U.S. biotech working on a cardiovascular drug, continuing what's been a flurry of acquisitions at a similar price point.
Novartis strikes $1.4bn deal for Tourmaline Bio
03:02am, Tuesday, 09'th Sep 2025
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthening its push into cardiovascular medicine with a late-stage anti-inflammatory drug candidate. The
Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal
02:02am, Tuesday, 09'th Sep 2025
The deal will boost the Swiss pharmaceutical company's cardiovascular drug pipeline.
Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion
01:15am, Tuesday, 09'th Sep 2025
Switzerland's Novartis will acquire Tourmaline Bio with an offer price of $48 per share, in a deal valuing the New York-based company at $1.4 billion on a fully diluted basis, it said on Tuesday.
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
01:03am, Tuesday, 09'th Sep 2025
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline's pacibekitug, a lon
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising targe
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
07:44am, Friday, 05'th Sep 2025
Shares in Arrowhead Pharmaceuticals (ARWR 0.72%) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned, in cl
Global drugmakers rush to boost US presence as tariff threat looms
02:09pm, Wednesday, 03'rd Sep 2025
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
10:46am, Wednesday, 03'rd Sep 2025
Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.
